Antiviral Drugs - United States

United States

The projected revenue in the Antiviral Drugs market in the United States is expected to reach €28.42bn by 2024.
It is anticipated that the revenue will show an annual growth rate (CAGR 2024-2029) of 1.57%, leading to a market volume of €30.72bn by 2029.
In comparison to other countries worldwide, United States is expected to generate the highest revenue, amounting to €28.42bn in 2024.
The United States is witnessing a surge in demand for antiviral drugs as a result of the ongoing COVID-19 pandemic.

Key regions: Brazil, India, Australia, United States, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Antiviral Drugs market in United States has been experiencing significant growth in recent years.

Customer preferences: Antiviral drugs are used to treat viral infections, and their demand has been increasing due to the rise of infectious diseases such as HIV, influenza, and hepatitis. Customers in the United States prefer antiviral drugs due to their effectiveness in treating viral infections.

Trends in the market: The Antiviral Drugs market in the United States has been growing due to the increasing prevalence of viral infections. The market is also being driven by the development of new antiviral drugs that are more effective than previous generations. In addition, the market is being driven by the increasing use of antiviral drugs in combination therapy, where multiple drugs are used in combination to treat viral infections.

Local special circumstances: The United States has a large population that is at risk of contracting viral infections. This has led to a high demand for antiviral drugs in the country. In addition, the United States has a well-developed healthcare system that is able to provide access to antiviral drugs to a large number of people.

Underlying macroeconomic factors: The growth of the Antiviral Drugs market in the United States is being driven by several macroeconomic factors. These include the increasing prevalence of viral infections, the development of new and more effective antiviral drugs, and the increasing use of antiviral drugs in combination therapy. In addition, the growth of the market is being driven by the well-developed healthcare system in the United States, which is able to provide access to antiviral drugs to a large number of people.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.